Didn't find any results in this catalog!
But we have some results in other catalogs.Filters
total: 13117
-
Catalog
- Publications 4626 available results
- Journals 28 available results
- People 355 available results
- Inventions 25 available results
- Projects 15 available results
- Laboratories 6 available results
- Research Teams 9 available results
- Research Equipment 50 available results
- e-Learning Courses 1919 available results
- Events 70 available results
- Open Research Data 6014 available results
displaying 1000 best results Help
Search results for: HIV-1
-
Inhibition of HIV‐1 or bacterial activation of macrophages by products of HIV‐1‐resistant human cells
Publication -
Induction of Secreted Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Factors in CD4-Positive T Lymphocytes by Attenuated HIV-1 Infection
Publication -
Value of Perfusion-Weighted MR Imaging in the Assessment of Early Cerebral Alterations in Neurologically Asymptomatic HIV-1-Positive and HCV-Positive Patients
Publication -
Hepatitis D, B and C virus (HDV/HBV/HCV) coinfection as a diagnostic problem and therapeutic challenge
Publication -
Microarray analysis of differentially expressed genes in cells resistant to HIV-1
Publication -
Monoubiquitinated Histone H1B Is Required for Antiviral Protection in CD4+T Cells Resistant to HIV-1
Publication -
Assessment of urinary cystatin C levels in HIV-1-infected patients with preserved kidney function
Publication -
Molecular basis and potential activity of HIV-1 reverse transcriptase toward trimethylamine-based compounds
PublicationReverse transcriptase (RT) inhibitors are currently used to treat human immunodeficiency virus (HIV)-1 infections. In this work, novel triethylamine derivatives were designed and studied by rigid and flexible docking and molecular dynamics (MD) approaches. An apo form of HIV-1 RT was also studied by MD simulation to analyze comparative response of protein in ligand-bound and ligand-unbound forms. Among newly designed HIV-1 RT inhibitors,...
-
Extracting functional groups of ALLINI to design derivatives of FDA‐approved drugs: Inhibition of HIV‐1 integrase
PublicationHIV‐1 integrase (IN) is crucial for integration of viral DNA into the host genome and a promising target in development of antiretroviral inhibitors. In this work, six new compounds were designed by linking the structures of two different class of HIV‐1 IN inhibitors (active site binders and allosteric IN inhibitors (ALLINIs)). Among newly designed compounds, INRAT10b was found most potent HIV‐1 IN inhibitor considering different...
-
Lancet HIV
Journals